Hey there, IBD warriors! We've got some exciting news to
share with you about a potential new treatment called Risankizumab for
ulcerative colitis (UC).
What is Risankizumab?
Risankizumab, an interleukin-23 (IL-23) inhibitor, is currently
marketed under the trade name Skyrizi and is approved for the treatment of
active psoriatic arthritis, moderately to severely active Crohn disease, and
moderate to severe plaque psoriasis.
Researchers are looking into it for people with UC. It’s
currently under review, which means doctors and scientists are checking to see
if it can help people with moderately to severely active UC.
Why is This Exciting?
Well, for those of us battling UC, having more treatment
options is a big deal. Sometimes our usual treatments don't work as well as
we'd hope, and that's where Risankizumab might come in.
What Does "Moderately to Severely Active" Mean?
When they say "moderately to severely active,"
they're talking about how bad your UC symptoms are. If your UC is causing you a
lot of trouble, like frequent bathroom trips, pain, and inflammation, you're in
the "moderately to severely active" category.
How Does Risankizumab Work?
Risankizumab is a type of biologic medicine which sticks to a
protein called IL-23. Your immune system makes IL-23 to help you fight
infections, but it can also cause inflammation. Risankizumab blocks the effects
of IL-23, reducing gut inflammation.
What's Next?
Right now, Risankizumab is going through a process called
"review." This means experts are looking at all the research and data
to decide if it's safe and effective for people with UC. If it gets the green light,
it could become another tool in our UC toolkit.
Stay Tuned!
We'll keep our eyes on this superhero medicine and let you
know if it becomes available. In the meantime, keep talking to your doctor
about your UC treatment plan, and don't forget that we're here to support each
other in this IBD journey. Together, we're stronger! 💪
💜
Comments
Post a Comment